Pulmatrix (NASDAQ:PULM) Now Covered by Analysts at StockNews.com

Research analysts at StockNews.com started coverage on shares of Pulmatrix (NASDAQ:PULM) in a report released on Friday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Pulmatrix Stock Performance

NASDAQ:PULM opened at $5.91 on Friday. The stock’s fifty day moving average price is $4.21 and its two-hundred day moving average price is $2.81. The company has a market cap of $21.58 million, a price-to-earnings ratio of -2.24 and a beta of 1.54. Pulmatrix has a 52-week low of $1.55 and a 52-week high of $8.44.

About Pulmatrix

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.